S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.55
    -0.20 (-1.86%)

    Market Cap: $655.77M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(9/13)
    Avg Surprise
    -506.85%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.28 - $-0.16
    9 analysts
    EPS Revisions
    4
    0
    7d
    7
    0
    30d
    EPS Estimate Drift
    90d ago$-0.40-55.9%
    60d ago$-0.27-4.2%
    30d ago$-0.27-4.2%
    7d ago$-0.27-4.2%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.33
    Range$-0.61 - $-0.09
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.33---
    Sep 26EST
    		-$-0.26---
    Jun 26
    		$-0.26$-0.28+7.14%Beat+18.8%
    Mar 26
    		$-0.33$-0.35+5.71%Beat+41.1%
    Dec 25
    		$-0.29$-0.40+27.79%Beat+42.0%
    Sep 25
    		$-0.40$-0.39-2.56%Miss+11.1%
    Jun 25
    		$-0.32$-0.50+36.00%Beat-28.0%
    Mar 25
    		$-0.56$-0.71+21.13%Beat-143.5%
    Dec 24
    		$-0.50$-0.65+23.08%Beat+35.9%
    Sep 24
    		$-0.45$-0.40-12.50%Miss-28.6%
    Jun 24
    		$-0.25$-0.35+28.57%Beat+99.3%
    Mar 24
    		$-0.23$-0.38+39.47%Beat+47.7%
    Dec 23
    		$-0.78$-0.58-34.48%Miss-
    Sep 23
    		$-0.35N/A+56.25%Beat-
    Jun 23
    		$-35.80$-0.52-6784.62%Miss-
    Mar 23
    		$-0.44$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.24EV/EBITDA-1.93x
    Price/FCF-13.43xFCF Yield-7.45%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-24.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio45.02xQuick Ratio45.02x
    Trading Statistics
    Beta3.40Avg Volume1.35M
    52-Week High$11.1552-Week Low$4.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.47
    SMA 20$9.73
    SMA 50$8.29
    SMA 200$6.76
    EMA 10$10.33
    EMA 20$9.76
    EMA 50$8.66
    EMA 200$7.17

    MACD

    Line: 0.75Signal: 0.74Hist: 0.01

    ADX

    ADX: 40.5+DI: 30.6-DI: 11.0

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down24.0
    PSAR$11.06

    Bollinger Bands

    Upper Band$11.74
    Lower Band$7.71
    %B Position4144%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    67.6

    Momentum Oscillators

    Stoch %K81.1
    Stoch %D79.5
    Williams %R-28.8
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)72.0
    MFI (14d)60.2

    Volatility Measures

    ATR (14d)$0.56(5.3%)
    StdDev (20d)1.01
    Hist Vol73.6%(High)

    Volume Flow

    VWAP$10.61
    OBV89.6M
    AD Line-11.4M
    CMF (20d)0.227

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.4x(Low)
    VWMA (20d)$9.51

    Pivot Points

    R3$11.36
    R2$11.16
    R1$10.95
    Pivot Point$10.75
    S1$10.54
    S2$10.34
    S3$10.13

    Advanced Oscillators

    TSI41.54
    Ultimate Osc49.3
    KST367.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$2.00M
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$2.00M
    Operating Expenses$15.82M$11.71M$10.77M$14.33M$11.93M$19.86M$18.20M$16.90M$10.59M$8.77M$9.47M$9.45M
    R&D$11.54M$7.00M$6.73M$9.73M$7.25M$15.34M$14.22M$12.65M$6.31M$5.26M$5.66M$4.96M
    SG&A$4.28M$4.72M$4.03M$4.60M$4.68M$4.52M$3.98M$4.25M$4.28M$3.51M$3.81M$4.49M
    Operating Income$-15,818,000$-11,713,000$-10,765,000$-14,334,000$-11,925,000$-19,865,000$-18,195,000$-16,902,000$-10,589,000$-8,768,000$-9,466,000$-7,452,000
    Interest Income$1.86M$1.06M$1.20M$1.43M$1.54M$1.69M$1.99M$2.28M$2.47M$2.14M$1.31M$1.09M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-13,953,000$-10,650,000$-9,568,000$-12,908,000$-10,386,000$-18,176,000$-16,201,000$-14,619,000$-8,118,000$-6,629,000$-8,151,000$-6,353,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,953,000$-10,650,000$-9,568,000$-12,908,000$-10,386,000$-18,176,000$-16,201,000$-14,619,000$-8,118,000$-6,629,000$-8,151,000$-6,353,000
    EBITDA$-15,835,000$-11,853,000$-10,465,000$-14,262,000$-12,151,000$-20,400,000$-18,251,000$-17,429,000$-11,066,000$-8,961,000$-9,464,000$-7,448,000
    EBIT$-15,818,000$-11,713,000$-10,765,000$-14,334,000$-11,925,000$-19,865,000$-18,195,000$-16,902,000$-10,589,000$-8,768,000$-9,466,000$-7,448,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGMT

    News

    Sagimet Highlights Q2 Results and Dermatology Focus Shift

    Sagimet Biosciences (SGMT) reported its Q2 2026 results, announcing a strategic pivot towards dermatology. The company plans to advance its lead FASN inhibitor, denifanstat, into a U.S. Phase 3 acne trial and progress TVB-3567, backed by $257.6 million in cash which is expected to fund operations through 2028. Despite rising R&D costs and a widening net loss, Sagimet gained market visibility through inclusion in the Russell 3000 and 2000 indices.

    TipRanks•8/11/26•
    Somewhat-Bullish

    BlackRock (NYSE: BLK) reports 7.8% beneficial stake in Sagimet Biosciences (SGMT)

    BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Sagimet Biosciences Inc. (SGMT) Class A Stock, as reported in a Schedule 13G filing. As of June 30, 2026, BlackRock's business units beneficially owned 4,751,186 shares and held sole voting power over 4,690,270 shares. No single BlackRock client holds more than 5% of Sagimet's outstanding common shares.

    Stock Titan•7/30/26•
    Neutral

    Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – DUS:0O2

    This article provides financial data on Sagimet Biosciences Inc. Class A, specifically its enterprise value to EBIT forward. It lists the company on the Dusseldorf Stock Exchange under the ticker 0O2, indicating that the market is currently closed with no trades. The content appears to be a financial data listing from TradingView, offering a snapshot of the company's financial overview.

    TradingView•7/27/26•
    Neutral

    Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – MUN:0O2

    This article provides financial information for Sagimet Biosciences Inc. Class A (MUN:0O2), focusing on its enterprise value to EBIT forward. It indicates various financial tools and data available for the company on TradingView, along with general market and community information.

    TradingView•7/20/26•
    Neutral

    Price to earnings forward of Sagimet Biosciences Inc. Class A – SWB:0O2

    This article provides access to the "Price to earnings forward" financial metric for Sagimet Biosciences Inc. Class A (SWB:0O2) on the Stuttgart Stock Exchange, as tracked by TradingView. It highlights that the market was closed with no trades at the time of the data. The content primarily serves as a gateway to financial data and various TradingView features.

    TradingView•7/4/26•
    Neutral

    Frequently Asked Questions About SGMT

    Does SGMT pay dividends?
    Sagimet Biosciences Inc. Series A Common Stock (SGMT) does not currently pay a regular dividend.
    What is SGMT's market cap?
    Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a market capitalization of $655.77M with a current stock price of $10.55.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In